Note - The COVID-19 Vaccine Group is based on the interim recommendations from ACIP. As additional guidelines are published, the COVID-19 logic in ICE will be updated. This release includes support for the following COVID-19 vaccines:
- Pfizer COVID-19 vaccine (CVX 208)
- Moderna COVID-19 vaccine (CVX 207)
- Janssen COVID-19 vaccine (CVX 212)
- COVID-19, Unspecified Formulation (CVX 213)
Two Shot Same Day Exception Rules for COVID-19
The Duplicate Shot, Same Day rules do not apply for COVID-19 Vaccine Group, due to the fact that the absolute minimum intervals between dose 1 and dose 2 = 0 days in both the Pfizer COVID-19 2-dose Series and Moderna COVID-19 2-dose Series.
Panel | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||
|
COVID-19 Vaccine Group Evaluation and Forecasting Rules
General Rules for COVID-19
General rules are not series-specific; general rules apply to the entire vaccine group.
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Rules for Recommending at the CVX Code vs. Vaccine Group Level
|
COVID-19 Vaccines
...
CVX Code
...
Name
...
Moderna COVID-19 Vaccine
...
208
...
Pfizer COVID-19 Vaccine
...
(*) If a COVID-19 vaccine is administered before the vaccine's minimum age or series' recommended age (16y - 4d for Pfizer; 18y - 4d for Moderna), or below the series' minimum interval, supplemental text is returned to alert the user of this fact even though the may have been evaluated as Valid. See "Series Special Rules" for all series below for more details. (Note: the running distribution must have the output_supplemental_text option enabled for the supplemental text to be returned.)
(*) See not about exception logic for AstraZeneca below.
Combination Vaccines that Include COVID-19
No combination vaccines exist, at this time, that include COVID-19 and count toward completion of the Pfizer COVID-19 2-dose series.This page specifies the COVID-19 logic implemented by ICE for recommendations before September 12, 2023.
For COVID-19 logic for recommendations as of September 12, 2023 onwards, see COVID-19 Vaccine Group - September 2023 Onwards.
Two Shot Same Day Exception Rules for COVID-19
For COVID-19 shots administered:
- before 10/25/2021, the Duplicate Shot, Same Day rules do NOT apply because absolute minimum intervals between dose 1 and dose 2 = 0 days (before 10/25/2021) in both the Pfizer COVID-19 2-dose series and Moderna COVID-19 2-dose series.
- on or after 10/25/2021, the Duplicate Shot, Same Day rules apply because absolute minimum intervals between dose 1 and dose 2 > 0 days (on or after 10/25/2021) in both the Pfizer COVID-19 2-dose series and Moderna COVID-19 2-dose series.
Panel | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||
|
COVID-19 Vaccine Group Evaluation and Forecasting Rules
General Rules for COVID-19
General rules are not series-specific; general rules apply to the entire vaccine group.
Panel | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||
Anchor |
|
Anchor | ||||
---|---|---|---|---|
|
- Once a patient completes:
- the Pfizer COVID-19 Series,
- and is < 5 years old:
- if the execution date is < 3/17/2023, the recommendation is Not Recommended and the reason code is COMPLETE.
- if the execution date is >= 3/17/2023 and a bivalent vaccine (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, or CVX 520) has not been administered, recommend a dose of COVID-19 at the vaccine group level and recommended interval (8 weeks) or on 3/17/2023, whichever date is latest, along with recommendation reasons ADMINISTER_COVID19_BIVALENT_VACCINE and SUPPLEMENTAL_TEXT and Descriptive Text: "Patients who previously completed a 3-dose monovalent primary series are recommended to receive 1 bivalent booster dose, at least 8 weeks after completion of the monovalent primary series.
- and is >= 5 years old:
- if the execution date is >= 4/19/2023:
- See Section "Rules for Booster Dose", Bullet Point: "After completion of the Pfizer COVID-19 Series, the execution date is >= 3/17/2023, and the patient is < 5 years of age"
- if the execution date is >= 4/19/2023:
- if the execution date is < 9/2/2022:
- and is >= 5 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (5 months) or at recommended age (5 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE.
if the execution date is >= 9/2/2022 and is < 4/19/2023:
and is >= 5 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks) or at recommended age (5 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE.
See “Rules for Booster Dose” for booster dose recommendations for the Pfizer COVID-19 Series.
- and is < 5 years old:
- the Mixed Product or Moderna COVID-19 Series,
- if the execution date is >= 4/19/2023:
- See Section "Rules for Booster Dose", Bullet Point: "After completion of the Pfizer COVID-19 Series, Mixed Product COVID-19 Series, Moderna COVID-19 Series, Janssen COVID-19 Series or Novavax COVID-19 Series, and the execution date is >= 4/19/2023"
- if the execution date is >= 12/9/2022 and < 4/19/2023:
- and is >= 6 months of age, recommend a booster dose of COVID-19 at recommended interval (8 weeks), recommended age (6 months) or on 12/9/2022, whichever date is latest, along with recommendation reason code BOOSTER_DOSE.
- if the execution date is >= 10/12/2022 and < 12/9/2022:
- and is >= 5 years and < 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks), recommended age (5 years) or on 10/12/2022, whichever date is latest, along with recommendation reason code BOOSTER_DOSE.
- if the execution date is >= 9/2/2022:
- and is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
- and is >= 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks), recommended age (12 years) or on 9/2/2022, whichever date is latest, along with recommendation reason code BOOSTER_DOSE.
See “Rules for Booster Dose” for booster dose recommendations for the Moderna COVID-19 Series.
- if the execution date is >= 4/19/2023:
- the Janssen COVID-19 Series,
- If the execution date is >= 4/19/2023:
- See Section "Rules for Booster Dose", Bullet Point: "After completion of the Pfizer COVID-19 Series, Mixed Product COVID-19 Series, Moderna COVID-19 Series, Janssen COVID-19 Series or Novavax COVID-19 Series, and the execution date is >= 4/19/2023"
- Otherwise:
- and is >= 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks), along with recommendation reason code BOOSTER_DOSE.
- and is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
See “Rules for Booster Dose” for booster dose recommendations for the Janssen COVID-19 Series.
- If the execution date is >= 4/19/2023:
- the Novavax COVID-19 Series,
- If the execution date is >= 4/19/2023:
- See Section "Rules for Booster Dose", Bullet Point: "After completion of the Pfizer COVID-19 Series, Mixed Product COVID-19 Series, Moderna COVID-19 Series, Janssen COVID-19 Series or Novavax COVID-19 Series, and the execution date is >= 4/19/2023"
- Otherwise:
- and is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
- and is >= 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks) or at recommended age (12 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE.
- If the execution date is >= 4/19/2023:
a COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine,
- if the execution date is < 9/2/2022:
recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (5 months) or at recommended age (12 years), whichever date is later, along with recommendation reason code BOOSTER_DOSE.
if the execution date is >= 10/12/2022:
and is >= 5 years and < 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks), recommended age (5 years) or on 10/12/2022, whichever date is latest, along with recommendation reason code BOOSTER_DOSE.
if the execution date is >= 9/2/2022:
and is < 12 years old, the recommendation is Conditional and the reason code is COMPLETE_HIGH_RISK.
and is >= 12 years old, recommend a booster dose of COVID-19 (at vaccine group level) at recommended interval (8 weeks), recommended age (12 years), or on 9/2/2022, whichever date is latest, along with recommendation reason code BOOSTER_DOSE.
See “Rules for Booster Dose” for booster dose recommendations for the these series.
- if the execution date is < 9/2/2022:
- the Pfizer COVID-19 Series,
Rules for an Additional Dose1
- If a patient completes a COVID-19 vaccine series via the Moderna COVID-19 Series or COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives an additional shot of CVX 207, CVX 208, CVX 211, CVX 212, CVX 213, CVX 217, CVX 218, CVX 219, CVX 221, CVX 227, CVX 228, CVX 229, CVX 300, CVX 301, CVX 302, CVX 519, CVX 520:
- if the execution date is < 9/2/2022:
- at < 5 months after series completion, then evaluate the shot as Valid / SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 5 months required for the 1st Booster Dose."
- at >= 5 months after series completion, then evaluate the shot as Valid.
- if the execution date is >= 9/2/2022 and < 4/19/2023:
- at < 8 weeks after series completion, then evaluate the shot as Valid / SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 8 weeks required for the 1st Booster Dose."
- at >= 8 weeks after series completion, then evaluate the shot as Valid.
- if the execution date is < 9/2/2022:
If a patient completes the COVID-19 vaccine series via the Pfizer COVID-19 Series or the Mixed Product COVID-19 Series and receives an additional shot of CVX 207, CVX 208, CVX 211, CVX 213, CVX 217, CVX 218, CVX 219, CVX 221, CVX 227, CVX 228, CVX 229, CVX 300, CVX 301, CVX 302, CVX 519, CVX 520:
if the patient is >= 5 years old and < 12 years old, or if the patient is >= 12 years old and the execution date is < 9/2/2022:
at < 5 months after series completion, then evaluate the shot as Valid / SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 5 months required for the 1st Booster Dose."
at >= 5 months after series completion, then evaluate the shot as Valid.
if the patient is >= 12 years old and the execution date is >= 9/2/2022 and < 4/19/2023:
at < 8 weeks after series completion, then evaluate the shot as Valid / SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 8 weeks required for the 1st Booster Dose."
at >= 8 weeks after series completion, then evaluate the shot as Valid.
If a patient completes a COVID-19 vaccine series via the Janssen COVID-19 Series or Novavax COVID-19 Series, and receives an additional shot is administered < 4/19/2023 of CVX 207, CVX 208, CVX 211, CVX 213, CVX 217, CVX 218, CVX 219, CVX 221, CVX 227, CVX 228, CVX 229, CVX 300, CVX 301, CVX 302, CVX 519, or CVX 520:
at < 8 weeks after series completion, then evaluate the shot as Valid / SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 8 weeks required for the 1st Booster Dose."
at >= 8 weeks after series completion, then evaluate the shot as Valid.
Rules for Booster Dose2
Any of the FDA-Approved COVID-19 vaccines (except CVX 218) can be used for booster vaccination, regardless of the vaccine product used for primary vaccination. When a heterologous or “mix and match” booster dose is administered, the eligible population and dosing intervals are those of the vaccine used for primary vaccination.
Recommendation Rules for Booster Dose or Requirement for a Dose with a Bivalent Vaccine
- Recommend at the Vaccine Group Level (along with recommendation reason code BOOSTER_DOSE)
- After completion of the Pfizer COVID-19 Series, Mixed Product COVID-19 Series, Moderna COVID-19 Series, Janssen COVID-19 Series, or Novavax COVID-19 Series, and the execution date is >= 4/19/2023:
- If the patient is >= 65 years of age and has had 2 or more prior doses with a bivalent vaccine (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, CVX 520) or 2 or more doses at >= 4/19/2023, recommend Not Recommended / COMPLETE.
- If the patient is >= 65 years of age and has had 1 prior dose with a bivalent vaccine (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, CVX 520) or 1 prior dose at >= 4/19/2023, recommend Not Recommended / COMPLETE_HIGH_RISK.
- If the patient is < 65 years of age and has had at least 1 prior dose with a bivalent vaccine (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, CVX 520) or at least 1 dose administered at >= 4/19/2023, recommend Not Recommended / COMPLETE.
- If the patient has not had any bivalent doses (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, CVX 520) or any doses administered at >= 4/19/2023, recommend a bivalent vaccine along with recommendation reason ADMINISTER_COVID19_BIVALENT_VACCINE (new recommendation reason code).
- Minimum Age = 6 months
- Recommended Age = 6 months
- Recommended Interval = 8 weeks
- After completion of the Pfizer COVID-19 Series, the execution date is >= 3/17/2023, and the patient is < 5 years of age:
- If the patient has had at least 1 prior dose with a bivalent vaccine (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, CVX 520), recommend Not Recommended / COMPLETE.
- If the patient has not had at least one prior bivalent doses (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, CVX 520), recommend a bivalent vaccine along with recommendation reason ADMINISTER_COVID19_BIVALENT_VACCINE:
- Minimum Age = 6 months
- Recommended Age = 6 months
- Recommended Interval = 8 weeks
- After completion of the Mixed Product COVID-19 Series or Moderna COVID-19 Series with execution date < 4/19/2023, Pfizer COVID-19 Series with execution date < 3/17/2023, or Janssen series, Novavax series, or COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine:
After completion of the First Booster Dose:
After completion of the Moderna COVID-19 Series
- If the execution date is < 9/2/2022:
Recommended Age = 18 years
Minimum Age = 18 years
Recommended Interval = 5 months
- If the execution date is >= 9/2/2022 and < 12/9/2022:
- Minimum Age = 5 years
- Recommended Age = 5 years
- Recommended Interval = 8 weeks
- If the execution date is >= 12/9/2022:
- Minimum Age = 6 months
- Recommended Age = 6 months
- Recommended Interval = 8 weeks
- If the execution date is < 9/2/2022:
After completion of the Pfizer COVID-19 Series or Mixed Product COVID-19 Series
- Minimum Age = 5 years
Recommended Age = 5 years
If the execution date is < 9/2/2022:
Recommended Interval = 5 months
- If the execution date is >= 9/2/2022:
- Recommended Interval = 8 weeks
After completion of Janssen COVID-19 Series
If the patient is >= 5 years of age and < 12 years of age:
Recommend Not Recommended / COMPLETE_HIGH_RISK.
- Otherwise:
Recommended Age = 12 years
Minimum Age = 12 years
Recommended Interval = 8 weeks
After completion of a COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine
Recommended Age = 12 years
Minimum Age = 12 years
If the execution date is < 9/2/2022:
Recommended Interval = 5 months
- If the execution date is >= 9/2/2022:
- Recommended Interval = 8 weeks
After completion of the Novavax COVID-19 Series
If the patient is < 12 years of age:
Recommend Not Recommended / COMPLETE_HIGH_RISK.
Otherwise:
Minimum Age = 12 years
Recommended Age = 12 years
Recommended Interval = 8 weeks
Second Booster Dose:
After completion of the first booster in the Moderna COVID-19 Series
If the execution date is < 9/2/2022:
If the patient is < 50 years of age, recommend Conditional / COMPLETE_HIGH_RISK.
Otherwise:
Minimum Age = 50 years
Recommended Age = 50 years
Recommended Interval = 4 months
If the execution date is >= 9/2/2022:
If a prior booster dose was administered >= 9/2/2022 and the patient is >= 12 years of age, recommend Not Recommended / COMPLETE.
If a prior booster dose was administered >= 10/12/2022 and < 12/9/2022, and the patient is >= 5 years of age and < 12 years of age, recommend Not Recommended / COMPLETE.
- If a prior booster dose was administered >= 12/9/2022, and the patient is >= 6 months of age, recommend Not Recommended / COMPLETE.
If execution date is < 12/9/2022:
Minimum Age = 5 years
Recommended Age = 5 years
Recommended Interval = 8 weeks
- If the execution date is >= 12/9/2022:
- Minimum Age = 6 months
- Recommended Age = 6 months
- Recommended Interval = 8 weeks
- After completion of the first booster dose in the Pfizer COVID-19 Series or Mixed Product COVID-19 Series
- If the execution date is < 9/2/2022:
- Minimum Age = 12 years
- Recommended Age = 12 years
- Recommended Interval = 4 months
- If the execution date is >= 9/2/2022:
- If a prior booster dose was administered >= 9/2/2022 and the patient is >= 12 years of age, recommend Not Recommended / COMPLETE_HIGH_RISK.
- If a prior booster dose was administered >= 10/12/2022 and the patient is >= 5 years of age and < 12 years of age, recommend Not Recommended / COMPLETE_HIGH_RISK.
- Otherwise:
- Minimum Age = 5 years
- Recommended Age = 5 years
- Recommended Interval = 8 weeks
- If the execution date is < 9/2/2022:
After completion of first booster dose in the Janssen COVID-19 Series:
If the patient is >= 5 years of age and < 18 years of age:
Recommend Not Recommended / COMPLETE_HIGH_RISK.
If the execution date is < 9/2/2022:
If the patient is >= 18 years of age and < 50 years of age:
if the first booster dose was a mRNA vaccine (CVX 207, CVX 208, CVX 213, CVX 217, or CVX 221), recommend Conditional / COMPLETE_HIGH_RISK.
if the first booster dose was the Janssen vaccine (CVX 212):
Recommended Age = 18 years
Recommended Interval = 4 months
If the patient is >= 50 years of age:
if the first booster dose was a mRNA vaccine (CVX 207, CVX 208, CVX 213, CVX 217, or CVX 221):
Recommended Age = 50 years
Recommended Interval = 4 months
if the first booster dose was the Janssen vaccine (CVX 212):
Recommended Age = 18 years
Recommended Interval = 4 months
If the execution date is >= 9/2/2022:
If a prior booster dose was administered >= 9/2/2022, recommend Not Recommended / COMPLETE_HIGH_RISK.
Otherwise:
Minimum Age = 18 years
Recommended Age = 18 years
Recommended Interval = 8 weeks
After completion of the first booster in a COVID-19 vaccine series not authorized by the FDA but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine:
If the execution date is < 9/2/2022:
If the patient is < 50 years of age, recommend Conditional / COMPLETE_HIGH_RISK.
Otherwise:
Minimum Age = 50 years
Recommended Age = 50 years
Recommended Interval = 4 months
If the execution date is >= 9/2/2022:
If a prior booster dose was administered >= 9/2/2022 and the patient is >= 12 years of age, recommend Not Recommended / COMPLETE_HIGH_RISK.
If a prior booster dose was administered >= 10/12/2022 and the patient is >= 5 years of age and < 12 years of age, recommend Not Recommended / COMPLETE_HIGH_RISK.
Otherwise:
Minimum Age = 5 years
Recommended Age = 5 years
Recommended Interval = 8 weeks
After completion of the 1st booster dose in the Novavax COVID-19 Series:
Recommend Not Recommended / COMPLETE.
- Third Booster Dose
- After completion of the second booster in the Moderna COVID-19 series:
If the execution date is < 9/2/2022:
Recommend Conditional / COMPLETE_HIGH_RISK.
If the execution date is >= 9/2/2022:
If a prior booster dose was administered >= 9/2/2022 and the patient is >= 12 years of age, recommend Not Recommended / COMPLETE_HIGH_RISK.
If a prior booster dose was administered >= 10/12/2022 and < 12/9/2022, and the patient is >= 5 years of age and < 12 years of age, recommend Not Recommended / COMPLETE_HIGH_RISK.
- If a prior booster dose was administered >= 12/9/2022, and the patient is >= 6 months of age, recommend Not Recommended / COMPLETE_HIGH_RISK.
- If execution date is < 12/9/2022:
Minimum Age = 5 years
Recommended Age = 5 years
Recommended Interval = 8 weeks
- If the execution date is >= 12/9/2022:
- Minimum Age = 6 months
- Recommended Age = 6 months
- Recommended Interval = 8 weeks
After completion of the second booster in the Pfizer COVID-19 Series, Mixed Product Series, Janssen COVID-19 Series, or vaccine series not authorized by the FDA but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine:
If the execution date is < 9/2/2022:
Recommend Conditional / COMPLETE_HIGH_RISK.
If the execution date is >= 9/2/2022:
If a prior booster dose was administered >= 9/2/2022 and the patient is >= 12 years of age, recommend Not Recommended / COMPLETE_HIGH_RISK.
If a prior booster dose was administered >= 10/12/2022 and the patient is >= 5 years of age and < 12 years of age, recommend Not Recommended / COMPLETE_HIGH_RISK.
Otherwise:
Minimum Age = 5 years
Recommended Age = 5 years
Recommended Interval = 8 weeks
- After completion of the second booster in the Moderna COVID-19 series:
After completion of needed bivalent doses and/or booster doses2 (must be bivalent mRNA), the Recommendation is Not Recommended and the reason code is COMPLETE.
Evaluation Rules for Booster Dose
- Absolute Minimum Interval = 0 days
- After completion of either the Pfizer COVID-19 Series, Mixed Product COVID-19 Series, Moderna COVID-19 Series, Janssen COVID-19 Series, Novavax COVID-19 Series, or COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, and a shot is administered >= 4/19/2023
- If the patient has not received any bivalent doses by having previously received a bivalent vaccine (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, or CVX 520) as either a booster dose at >= 9/2/2022 or as a dose in the primary series, or a prior dose administered was not administered >= 4/19/2023:
at < 8 weeks after series completion, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 8 weeks."
at >= 8 weeks after series completion, then evaluate the shot as Valid
- Otherwise:
- If the patient is < 65 years of age:
- If 1 or more previous doses that are bivalent vaccines (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, or CVX 520) were administered as either a booster dose at >= 9/2/2022 or as a dose in the primary series, or, alternatively, a prior dose was administered >= 4/19/2023, evaluate the shot as Accepted / EXTRA_DOSE. (See Extra Shots section.)
- If the patient is >= 65 years of age:
- If 2 or more previous doses that are bivalent vaccines (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, or CVX 520) were administered as either a booster dose at >= 9/2/2023 or as a dose in the primary series, or, alternatively, a prior dose was administered >= 4/19/2023, evaluate the shot as Accepted / EXTRA_DOSE. (See Extra Shots section.)
- If 1 previous bivalent dose that is a bivalent vaccine (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, or CVX 520) was administered as either a booster dose at >= 9/2/2023 or as a dose in the primary series, or, alternatively, a prior dose was administered >= 4/19/2023
at < 4 months after the most recent shot, then evaluate the shot as Valid/ SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 4 months."
at >= 4 months after the most recent shot, then evaluate the shot as Valid.
- If the patient is < 65 years of age:
- If the patient has not received any bivalent doses by having previously received a bivalent vaccine (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, or CVX 520) as either a booster dose at >= 9/2/2022 or as a dose in the primary series, or a prior dose administered was not administered >= 4/19/2023:
- After completion of the Pfizer COVID-19 Series, Mixed Product COVID-19 Series, Moderna COVID-19 Series, Janssen series, Novavax series, or COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, and a shot is administered < 4/19/2023:
- First Booster Dose:
- If a patient completes a COVID-19 vaccine series via the Pfizer COVID-19 Series, Moderna COVID-19 Series, Mixed Product COVID-19 Series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives a booster dose2 of CVX 207, CVX 208, CVX 211, CVX 212, CVX 213, CVX 217, CVX 218, CVX 219, CVX 221, CVX 227, CVX 228, CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, or CVX 520:
- if the shot administration date is < 9/2/2022:
- at < 5 months after series completion, then evaluate the shot as Valid / SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 5 months required for the 1st Booster Dose."
- at >= 5 months after series completion, then evaluate the shot as Valid.
- if the shot administration date is >= 9/2/2022:
at < 8 weeks after series completion, then evaluate the shot as Valid / SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 8 weeks required for the 1st Booster Dose."
at >= 8 weeks after series completion, then evaluate the shot as Valid
- if the shot administration date is < 9/2/2022:
- If a patient completes a COVID-19 vaccine series via the Janssen COVID-19 Series or Novavax COVID-19 Series and receives a booster dose2 of CVX 207, CVX 208, CVX 211, CVX 212, CVX 213, CVX 217, CVX 218, CVX 219, CVX 221, CVX 227, CVX 228, CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, CVX 520:
- at < 8 weeks after series completion, then evaluate the shot as Valid / SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 8 weeks required for the 1st Booster Dose."
- at >= 8 weeks after series completion, then evaluate the shot as Valid.
- If a patient completes a COVID-19 vaccine series via the Pfizer COVID-19 Series, Moderna COVID-19 Series, Mixed Product COVID-19 Series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives a booster dose2 of CVX 207, CVX 208, CVX 211, CVX 212, CVX 213, CVX 217, CVX 218, CVX 219, CVX 221, CVX 227, CVX 228, CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, or CVX 520:
- Second Booster Dose:
If a patient completes a COVID-19 vaccine series via the Pfizer COVID-19 Series, Moderna COVID-19 Series, Mixed Product COVID-19 Series, Janssen COVID-19 Series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives a booster dose2 of CVX 207, CVX 208, CVX 211, CVX 212, CVX 213, CVX 217, CVX 218, CVX 219, CVX 221, CVX 227, CVX 228, CVX 229, CVX 230, CVX 300, CVX 301. CVX 302, CVX 519, or CVX 520:
If the first booster dose was administered >= 9/2/2022, evaluate the shot as Accepted / EXTRA_DOSE. (See Extra Shots section.)
If the second booster was administered < 9/2/2022:
at < 4 months after the first booster dose, then evaluate the shot as Valid / SUPPLEMENTAL_TEXT; Descriptive Text: “The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 4 months required for the 2nd Booster Dose."
at >= 4 months after the first booster dose, evaluate the shot as Valid.
If the second booster was administered >= 9/2/2022:
at < 8 weeks after series completion, then evaluate the shot as Valid / SUPPLEMENTAL_TEXT; Descriptive Text: "The timing of the administration of this shot does not follow the guidelines regarding the minimum interval of 8 weeks required for the 1st Booster Dose."
at >= 8 weeks after series completion, then evaluate the shot as Valid.
Third Booster Dose:
If a patient completes a COVID-19 vaccine series via the Pfizer COVID-19 Series, Moderna COVID-19 Series, Mixed Product COVID-19 Series, Janssen COVID-19 Series, COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine and receives a third booster dose2 of CVX 207, CVX 208, CVX 211, CVX 212, CVX 213, CVX 217, CVX 218, CVX 219, CVX 221, CVX 227, CVX 228, CVX 229, CVX 230, CVX 300, CVX 301, CVX 302, CVX 519, or CVX 520:
If a prior booster dose was a bivalent booster vaccine (CVX 229, CVX 230, CVX 300, CVX 301, CVX 302), evaluate the shot as Accepted / EXTRA_DOSE. (See Extra Shots section.)
Otherwise:
If the third booster dose is administered at < 8 weeks - 4 days after the second booster dose, evaluate the shot as Invalid / BELOW_MINIMUM_INTERVAL.
If the third booster dose is administered at >= 8 weeks - 4 days after the 2nd booster dose, evaluate the shot as Valid.
- First Booster Dose:
Rules for Evaluation of Extra Shots After Additional Dose1 and/or Booster Doses and/or Needed Bivalent Dose2
- For patients that completed the Pfizer COVID-19 Series or Mixed Product Series:
If the shot is administered < 9/2/2022:
is > = 5 years old and < 50 years old and received an Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is >= 50 years of age and Additional Dose and/or Booster Dose, and 2nd Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
and Additional Dose and/or 1st Booster Dose and 2nd Booster Dose, any shots administered afterwards will be Accepted/EXTRA_DOSE.
- If the shot is administered >= 9/2/2022 and < 4/19/2023:
- is >= 5 years old and < 12 years old and received an Additional Dose and/or Booster Dose >= 10/12/2022, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is >= 12 years old and an Additional Dose and/or a Booster Dose was administered >= 9/2/2022, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- is >= 6 months of age and received an Additional Dose and/or Booster Dose >= 3/17/2023 and < 4/19/2023, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- If the shot is administered >= 4/19/2023:
- is >= 6 months old and < 65 years old and received an Additional Dose and/or a Booster Dose administered >= 9/2/2022, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- is >= 65 years old and received two or more Additional Dose(s) and/or a Booster Dose(s) administered >= 9/2/2022, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- Any shots administered afterwards will be evaluated as Accepted / EXTRA_DOSE.
- For patients that completed the Janssen or Novavax series:
- if the patient is < 5 years old in Novavax and Janssen Series, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
If the shot is administered < 9/2/2022:
is > = 5 years old and < 50 years old and received an Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is >= 50 years of age and Additional Dose and/or Booster Dose, and 2nd Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
and Additional Dose and/or 1st Booster Dose and 2nd Booster Dose, any shots administered afterwards will be Accepted/EXTRA_DOSE.
- If the shot is administered >= 9/2/2022:
is >= 5 years old and < 12 years old and received an Additional Dose and/or Booster Dose >= 10/12/2022, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is >= 12 years old and received an Additional Dose and/or a Booster Dose was administered >= 9/2/2022, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
Any shots administered afterwards will be evaluated as Accepted / EXTRA_DOSE.
For patients that completed the Moderna COVID-19 series:
- If the shot is administered < 9/2/2022:
- is < 5 years old, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is >= 5 years old and < 18 years old and received an Additional Dose, any shots administered afterwards at < 18 years of age will be evaluated as Accepted/EXTRA_DOSE
is > = 18 years old and < 50 years old and received an Additional Dose and/or Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is >= 50 years of age and received an Additional Dose and/or Booster Dose, and 2nd Booster Dose, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- If the shot is administered >= 9/2/2022 and < 4/19/2023:
- is >= 6 months old and received an Additional Dose and/or Booster Dose >= 12/9/2022, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is >= 5 years old and < 12 years old and received an Additional Dose and/or Booster Dose >= 10/12/2022, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
is >= 12 years old and received an Additional Dose and/or a Booster Dose was administered >= 9/2/2022, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- If the shot is administered >= 4/19/2023:
- is >= 6 months old and < 65 years old and received an Additional Dose and/or a Booster Dose administered >= 9/2/2022, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- is >= 65 years old and received two or more Additional Dose(s) and/or a Booster Dose(s) administered >= 9/2/2022, any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
Any shots administered afterwards will be evaluated as Accepted/EXTRA_DOSE.
- If the shot is administered < 9/2/2022:
For patients that completed either the 1) COVID-19 vaccine series not authorized by the FDA, but authorized by the WHO, or a 2) COVID-19 vaccine series not authorized by the FDA or WHO, but is an active COVID-19 vaccine candidate as part of a U.S.-based clinical trial of a COVID-19 vaccine, Additional Dose and/or 3 Booster Dose, any shots administered after the primary series is evaluated as Accepted/EXTRA_DOSE.
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Notes
|
COVID-19 Vaccines
CVX Code | Name | Absolute Minimum Age | Absolute Maximum Age | Counts towards U.S. Vaccination |
---|---|---|---|---|
207 | Moderna COVID-19 Vaccine | 0 days | Yes | |
208 | Pfizer COVID-19 Vaccine | 0 days | Yes | |
210 | AstraZeneca COVID-19 Vaccine | 0 days | Yes | |
211 | Novavax COVID-19 Vaccine | 0 days | Yes | |
212 | Janssen COVID-19 Vaccine | 0 days | Yes | |
213 | SARS-COV-2 (COVID-19) vaccine, UNSPECIFIED | 0 days | Yes | |
217 | Pfizer COVID-19 Vaccine (>= 12 years) | 0 days | Yes | |
218 | Pfizer COVID-19 Vaccine | 0 days | 18 years - 1 day | Yes |
219 | Pfizer COVID-19 Vaccine | 0 days | 6 years - 1 day | Yes |
221 | Moderna COVID-19 Vaccine | 0 days | Yes | |
227 | Moderna COVID-19 Vaccine (Inactive) | 0 days | 13 years - 1 day | Yes |
228 | Moderna COVID-19 Vaccine | 0 days | 7 years - 1 day | Yes |
229 | Moderna COVID-19 Vaccine, Bivalent | 0 days | Yes | |
230 | Moderna, COVID-19 Vaccine, Bivalent Booster | 0 days | 7 years - 1 day | Yes |
300 | Pfizer COVID-19 Vaccine, Bivalent | 0 days | Yes | |
301 | Pfizer COVID-19 Vaccine, Bivalent | 0 days | 12 years - 1 day | Yes |
302 | Pfizer, COVID-19 Vaccine, Bivalent | 0 days | 6 years - 1 day | |
500 | COVID-19 Non-US Vaccine, Product Unknown | No | ||
501 | COVID-19 IV Non-US Vaccine (QAZCOVID-IN) | No | ||
502 | COVID-19 IV Non-US Vaccine (COVAXIN) | 0 days | Yes | |
503 | COVID-19 LAV Non-US Vaccine (COVIVAC) | No | ||
504 | COVID-19 VVnr Non-US Vaccine (Sputnik Light) | No | ||
505 | COVID-19 VVnr Non-US Vaccine (Sputnik V) | No | ||
506 | COVID-19 VVnr Non-US Vaccine (CanSino Biological Inc./Beijing Institute of Biotechnology) | No | ||
507 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom Biopharmaceutical + Institute of Microbology Chinese academy of Sciences) | No | ||
508 | COVID-19 PS Non-US Vaccine (Jiangsu Province Centers for Disease Control and Prevention) | No | ||
509 | COVID-19 PS Non-US Vaccine (EpiVacCorona) | No | ||
510 | COVID-19 IV Non-US Vaccine (BIBP, Sinopharm) | 0 days | Yes | |
511 | COVID-19 IV Non-US Vaccine (CoronaVac, Sinovac) | 0 days | Yes | |
512 | COVID-19 VLP Non-US Vaccine (Medicago, Covifenz) | 18 years - 4 days | Yes | |
513 | COVID-19 PS Non-US Vaccine (Anhui Zhifei Longcom, Zifivax) | No | ||
514 | COVID-19 DNA Non-US Vaccine (Zydus Cadila, ZyCoV-D) | No | ||
515 | COVID-19 PS Non-US Vaccine (Medigen, MVC-COV1901) | No | ||
516 | COVID-19 Inactivated Non-US Vaccine (Minhai Biotechnology Co, KCONVAC) | No | ||
517 | COVID-19 PS Non-US Vaccine (Biological E Limited, Corbevax) | No | ||
518 | COVID-19 Inactivated, Non-US Vaccine (VLA2001, Valneva) | No | ||
519 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine (Spikevax Bivalent), Moderna | 0 days | Yes | |
520 | COVID-19 mRNA, bivalent, original/Omicron BA.1, Non-US Vaccine Product, Pfizer-BioNTech | 0 days | Yes | |
521 | COVID-19 SP, protein-based, adjuvanted (VidPrevtyn Beta), Sanofi-GSK | No |
Combination Vaccines that Include COVID-19
No combination vaccines exist, at this time, that include COVID-19 and count toward completion of the Pfizer COVID-19 2-dose series.
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
CVX Code Specific RulesCVX Code Absolute Minimum Age
CVX Code Absolute Maximum Age
Rule for CVX 218, CVX 219, CVX 227, CVX 228, CVX 229, CVX 230, CVX 301, CVX 302
Rule for Bivalent Vaccines (CVX 229, CVX 230, CVX 300, CVX 301, CVX 301, CVX 519, CVX 520)
Rule for CVX 213
Rules for COVID-19 Vaccines Not Authorized by FDA2The following set of rules apply to 1) COVID-19 Vaccines Not Authorized by FDA, but Authorized by WHO and, 2) COVID-19 Vaccines Not Authorized by FDA or WHO, but is an Active COVID-19 Vaccine Candidate as part of a U.S.-based Clinical Trial of a COVID-19 Vaccine.
|
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Notes
|
Immunization Series and Selection Rules
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Name
Series Selection RulesThere are five series for this vaccine group: Pfizer COVID-19 Series, Moderna COVID-19 Series, Mixed Product COVID-19 Series, Janssen COVID-19 Series, and Novavax COVID-19 Series. The rules for determining which series applies are:
|
Immunization Series: Pfizer COVID-19 Series
The Pfizer COVID-19 Series is complete after 2 or 3 doses, depending on age (not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum Age | Minimum Age | Routine Age | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 | Pfizer COVID-19 Series | 0 days | 6 months | 6 months | N/A | 208, 217, 218, 219, 300, 301, 302 | 229, 230 |
2 | Pfizer COVID-19 Series | 0 days | 6 months | 6 months | N/A | 208, 217, 218, 219, 300, 301, 302 | 229, 230 |
3 | Pfizer COVID-19 Series | 0 days | 6 months | 6 months | N/A | 208, 217, 218, 219, 300, 301, 302 | 229, 230 |
Vaccine Dose Parameters - Minimum and Recommended Intervals
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) |
---|---|---|---|---|---|
Dose 1 to 2 | Pfizer COVID-19 Series | 8 weeks - 4 days if dose 2 administered >= 4/19/2023 and dose 1 administered >= 5 years of age Otherwise, 17 days | 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 5 years of age Otherwise, 21 days | 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 5 years of age Otherwise, 21 days |
N/A |
Dose 2 to 3 | Pfizer COVID-19 Series | 8 weeks - 4 days | 8 weeks | 8 weeks | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Vaccine to Recommend
Skip Dose Rule
Rule for CVX 212 (Janssen COVID-19 vaccine)
|
Immunization Series: Moderna COVID-19 Series
The Moderna COVID-19 series is complete after 2 doses(not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum | Minimum Age | Routine | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 | Moderna COVID-19 Series | 0 days | 6 months | 6 months | N/A | 207, 221, 227, 228, 229 | N/A |
2 | Moderna COVID-19 Series | 0 days | 6 months | 6 months | N/A | 207, 221, 227, 228, 229 | N/A |
Vaccine Dose Parameters - Minimum and Recommended Intervals
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) |
---|---|---|---|---|---|
Dose 1 to 2 | Moderna COVID-19 | 0 days if dose 2 administered < 10/25/2021 8 weeks - 4 days if dose 2 administered >= 4/19/2023 and dose 1 administered >= 6 years of age Otherwise, 24 days if dose 2 administered >= 10/25/2021 | 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 6 years of age Otherwise, 28 days | 8 weeks if the execution date is >= 4/19/2023 and dose 1 administered >= 6 years of age Otherwise, 28 days | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
CVX Code Specific RulesCVX Code Absolute Minimum Age
Rule for CVX 213
Vaccine to Recommend
Rule for CVX 212 (Janssen COVID-19 vaccine)
|
Immunization Series: Mixed Product COVID-19
...
Rule for CVX 210 (AstraZeneca COVID-19 Vaccine)1
- If the patient has received CVX 210 (AstraZeneca COVID-19 vaccine) for Target Dose 1 and Target Dose 2, then:
- Evaluate both shots as Valid.
- No additional doses of COVID-19 vaccine are needed; Recommendation: Not Recommended/ COMPLETE.
- If the patient has received CVX 210 (AstraZeneca COVID-19 vaccine) for Target Dose 1 only, then:
- Evaluate the shot as Accepted/ VACCINE_NOT_APPROVED_IN_US. (new reason code)
- Recommendation:
- If CVX 210 is the last COVID-19 shot administered, then recommend COVID-19 at the vaccine group level at last shot administered + recommended interval (28 days).
- Example #1: Patient has 1 shot of CVX 210 (AstraZeneca) on record.
- Evaluate CVX 210 as Accepted/ VACCINE_NOT_APPROVED_IN_US.
- Recommend COVID-19 at the vaccine group level at CVX 210 + recommended interval (28 days).
- Example #2: Patient has 1 shot of CVX 208 (Pfizer), then 1 shot of CVX 210 (AstraZeneca) on record.
- Evaluate CVX 208 as Valid and CVX 210 as Accepted/ VACCINE_NOT_APPROVED_IN_US.
- Recommend COVID-19 at the vaccine group level at CVX 210 + recommended interval (28 days).
- Example #1: Patient has 1 shot of CVX 210 (AstraZeneca) on record.
- If CVX 210 is not the last COVID-19 shot administered, recommend based on the series that applies for the last COVID-19 shot administered.
- Example: If CVX 208 (Pfizer) is given after CVX 210 (AstraZeneca), then recommend based on the Pfizer COVID-19 2-dose Series.
- If CVX 210 is the last COVID-19 shot administered, then recommend COVID-19 at the vaccine group level at last shot administered + recommended interval (28 days).
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Notes
|
...
Series
The Mixed Product COVID-19 Series is complete after 2 or 3 doses, depending on age(not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum | Minimum Age | Routine | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 | Mixed Product COVID-19 Series | 0 days | 6 months | 6 months | N/A | 207, 208, 211, 213, 217, 218, 219, 221, 227, 228, 300, 301, 302 | 229, 230 |
2 | Mixed Product COVID-19 Series | 0 days | 6 months | 6 months | N/A | 207, 208, 211, 213, 217, 218, 219, 221, 227, 228, 300, 301, 302 | 229, 230 |
3 | Mixed Product COVID-19 Series | 0 days | 6 months | 6 months | N/A | 207, 208, 211, 213, 217, 218, 219, 221, 227, 228, 300, 301, 302 | 229, 230 |
Vaccine Dose Parameters - Minimum and Recommended Intervals
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) |
---|---|---|---|---|---|
Dose 1 to 2 | Mixed Product COVID-19 Series | 8 weeks - 4 days if dose 2 administered >= 4/19/2023 and dose 1 administered >= 5 years of age Otherwise:
| 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 5 years of age Otherwise, 28 days | 8 weeks if the execution date is >= 4/19/2023 and dose 1 was administered >= 5 years of age Otherwise, 28 days | N/A |
Dose 2 to 3 | Mixed Product COVID-19 Series | 8 weeks - 4 days | 8 weeks | 8 weeks | N/A |
Panel |
---|
...
Doses
...
Series Name
...
Absolute Minimum Interval
...
Minimum Recommended Interval
...
Dose 1 to 2
...
Pfizer COVID-19 2-dose Series
...
0 days
...
21 days
...
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
| ||||||||
Series Name
Series Selection RulesThere are three series for this vaccine group: the Pfizer COVID-19 2-dose series, Moderna COVID-19 2-dose series, and Janssen COVID-19 1-dose series. The rules for determining which series applies are:
|
Immunization Series: Pfizer COVID-19 2-dose Series
The Pfizer COVID-19 2dose series is complete after 2 doses.
Vaccine Dose Parameters - Minimum and Routine Ages
...
Dose
...
Series Name
...
Absolute Minimum
Age
...
Routine
Age
...
1
...
Pfizer COVID-19 2-dose Series
...
0 days
...
2
...
Pfizer COVID-19 2-dose Series
...
0 days
...
12 years
...
Vaccine Dose Parameters - Minimum and Recommended Intervals
...
Dose
...
Series Name
...
Absolute Minimum
Age
...
Routine
Age
...
Latest Recommended Age (less than)
...
1
...
Moderna COVID-19 2-dose Series
...
0 days
...
18 years
...
N/A
...
2
...
Moderna COVID-19 2-dose Series
...
| |||
Series Special Rules
Vaccine to Recommend
Skip Dose Rule
Rule for CVX 211 (Novavax COVID-19 vaccine)
Rule for CVX 212 (Janssen COVID-19vaccine)
|
Immunization Series: Moderna COVID-19 2-dose series
The Moderna COVID-19 2-dose series is complete after 2 doses.
Vaccine Dose Parameters - Minimum and Routine Ages
|
Immunization Series: Janssen COVID-19 Series
The Janssen COVID-19 Series is complete after 1 dose.
Vaccine Dose Parameters - Minimum and Recommended IntervalsRoutine Ages
Dose | Series Name | Absolute Minimum |
---|
| Minimum |
---|
Age | Routine | Latest Recommended |
---|
Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|
1 |
Janssen COVID-19 |
Series | 0 days |
18 years | 18 years | N/A | 212 | N/A |
Panel | ||||||||
---|---|---|---|---|---|---|---|---|
| ||||||||
Series Special Rules
Rule for CVX 212 (Janssen COVID-19 Vaccine)
|
Immunization Series:
...
Novavax COVID-19
...
Series
The Janssen Novavax COVID-19 1-dose Series is complete after 1 dose 2 doses (not including booster dose(s)).
Vaccine Dose Parameters - Minimum and Routine Ages
Dose | Series Name | Absolute Minimum | Minimum Age | Routine | Latest Recommended Age (less than) | Valid CVX Code(s) per Dose for this Series | Invalid CVX Code(s) per Dose for this Series |
---|---|---|---|---|---|---|---|
1 |
Novavax COVID-19 |
Series |
12 years - 4 days |
12 years |
12 years | N/A |
211 | |||||
2 | Novavax COVID-19 Series | 12 years - 4 days | 12 years | 12 years | N/A |
...
borderColor | #CCFFFF |
---|---|
bgColor | #CCFFFF |
titleBGColor | #99FFFF |
borderStyle | solid |
Series Special Rules
...
211 |
Vaccine Dose Parameters - Minimum and Recommended Intervals
Doses | Series Name | Absolute Minimum Interval | Minimum Interval | Recommended Interval | Latest Recommended Interval (less than) |
---|---|---|---|---|---|
Dose 1 to 2 | Novavax COVID-19 Series | 17 days | 21 days | 21 days | 8 weeks |